Intech Investment Management LLC Acquires Shares of 33,919 Alphatec Holdings, Inc. (NASDAQ:ATEC)

Intech Investment Management LLC bought a new position in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 33,919 shares of the medical technology company’s stock, valued at approximately $189,000.

Several other institutional investors and hedge funds have also made changes to their positions in ATEC. Point72 Asset Management L.P. grew its stake in Alphatec by 65.2% during the 2nd quarter. Point72 Asset Management L.P. now owns 3,192,789 shares of the medical technology company’s stock worth $33,365,000 after buying an additional 1,260,137 shares during the last quarter. Magnetar Financial LLC acquired a new position in shares of Alphatec in the 2nd quarter valued at $10,957,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its holdings in shares of Alphatec by 23.8% in the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,630,244 shares of the medical technology company’s stock valued at $27,486,000 after acquiring an additional 505,202 shares during the period. Granite Investment Partners LLC boosted its stake in Alphatec by 130.2% during the 2nd quarter. Granite Investment Partners LLC now owns 664,201 shares of the medical technology company’s stock worth $6,941,000 after purchasing an additional 375,621 shares during the period. Finally, AlphaCentric Advisors LLC acquired a new stake in Alphatec during the 3rd quarter worth $2,057,000. 66.35% of the stock is owned by hedge funds and other institutional investors.

Alphatec Stock Up 0.4 %

ATEC opened at $9.63 on Friday. The business has a 50 day simple moving average of $7.55 and a 200-day simple moving average of $8.18. Alphatec Holdings, Inc. has a 12 month low of $4.88 and a 12 month high of $17.34. The stock has a market capitalization of $1.36 billion, a P/E ratio of -7.52 and a beta of 1.38. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15.

Analyst Ratings Changes

A number of equities research analysts have recently commented on ATEC shares. Barclays upped their target price on shares of Alphatec from $19.00 to $20.00 and gave the company an “overweight” rating in a report on Tuesday, November 19th. Lake Street Capital decreased their price objective on Alphatec from $32.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday, September 3rd. Needham & Company LLC reiterated a “buy” rating and issued a $13.00 target price on shares of Alphatec in a research note on Thursday, October 31st. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Alphatec in a research note on Thursday, October 31st. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $20.00 price objective on shares of Alphatec in a research report on Friday, August 30th. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $17.11.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.